Retrophin no more: Shkreli's legacy disappears as former company becomes Travere Therapeutics
Retrophin is shedding the last of its ties to convicted “Pharma Bro” Martin Shkreli and his failed neurological drug — with a name change.
“That name doesn’t reflect who we are today, and the role that we want to play going into the future. So we felt that it was befitting to have a name that every single one of us came to work and can identify with,” CEO Eric Dube told Endpoints News.
The biotech, which was founded in 2011 by Shkreli, now goes by Travere Therapeutics, inspired by the Latin roots of the words “path” (tractus) and “truth” (ver). Dube said the rebranding has been in the works since he joined the company last year, and represents “the tireless journey that many rare disease families embark on to reach a diagnosis and ultimately a treatment or cure.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.